Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.81
+0.65007.10%
Pre-market: 9.75-0.0600-0.61%04:46 EDT
Volume:9.24M
Turnover:88.43M
Market Cap:2.46B
PE:8.11
High:9.98
Open:9.15
Low:9.05
Close:9.16
52wk High:11.31
52wk Low:6.00
Shares:250.80M
Float Shares:218.00M
Volume Ratio:1.15
T/O Rate:4.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:587.33%
ROA:43.21%
PB:-20.65
PE(LYR):8.11

Loading ...

BRIEF-Biocryst Receives Early Termination Of Hart-Scott-Rodino Waiting Period For Astria Acquisition

Reuters
·
Dec 03, 2025

BioCryst Pharmaceuticals-Astria Deal Clears Regulatory Hurdle

MT Newswires Live
·
Dec 03, 2025

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Reuters
·
Dec 03, 2025

BioCryst Pharmaceuticals Inc - Expects Merger to Close in Q1 2026

THOMSON REUTERS
·
Dec 03, 2025

How New Pediatric APeX-P Data at BioCryst (BCRX) Has Changed Its Investment Story

Simply Wall St.
·
Dec 02, 2025

BioCryst (BCRX) Receives a Buy from Wedbush

TIPRANKS
·
Nov 19, 2025

Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Promising Pediatric ORLADEYO Trial Results and FDA Review Updates

Simply Wall St.
·
Nov 19, 2025

BioCryst Director Machelle Sanders Reports Sale of Common Shares

Reuters
·
Nov 18, 2025

Did BioCryst's (BCRX) ORLADEYO Revenue Guidance and Pediatric Data Just Shift Its Investment Narrative?

Simply Wall St.
·
Nov 15, 2025

BioCryst to Acquire Astria Therapeutics for $8.55 Per Share and Stock

Reuters
·
Nov 12, 2025

BioCryst Unveils Data Showing ORLADEYO Cuts HAE Attacks in Children in Yearlong Trial

Reuters
·
Nov 06, 2025

BioCryst Presents New Data at Acaai Highlighting Burden of Hae on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated With One Year of Orladeyo® (Berotralstat)

THOMSON REUTERS
·
Nov 06, 2025

Stock Track | BioCryst Pharmaceuticals Soars 5.03% Pre-Market on Conference Presentation and Positive Analyst Rating

Stock Track
·
Nov 05, 2025

Stock Track | BioCryst Pharmaceuticals Plummets 5.03% as Analysts Cut Price Targets

Stock Track
·
Nov 04, 2025

BioCryst Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Nov 04, 2025

Barclays Sticks to Their Hold Rating for BioCryst (BCRX)

TIPRANKS
·
Nov 04, 2025

U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx, Cardinal Health

Reuters
·
Nov 04, 2025

BioCryst Pharmaceuticals Inc : Needham Cuts Target Price to $18 From $20

THOMSON REUTERS
·
Nov 04, 2025

BioCryst (BCRX) Gets a Buy from Needham

TIPRANKS
·
Nov 04, 2025

Stock Track | BioCryst Pharmaceuticals Plummets 5.33% as Q3 Revenue Misses Estimates Despite EPS Beat

Stock Track
·
Nov 03, 2025